Kunihiko Itoh

Kunihiko Itoh

Auto-generated profile, based on publicly available information

Kunihiko Itoh

Department of Clinical Pharmacology and Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
KHKeita Hirai
Keita Hirai
TSToshihiro Shirai
Toshihiro Shirai
MSMasayuki Suzuki
Masayuki Suzuki
TATaisuke Akamatsu
Taisuke Akamatsu
TSTakahito Suzuki
Takahito Suzuki
KIKunihiko Itoh
Kunihiko Itoh

25 July 2020 in Allergy
Verified
Journal Article
Closed access
PDF file
KHKeita Hirai
Keita Hirai
TSToshihiro Shirai
Toshihiro Shirai
TSTakayuki Shimoshikiryo
Takayuki Shimoshikiryo
MUMegumi Ueda
Megumi Ueda
YGYasuhiro Gon
Yasuhiro Gon
KIKunihiko Itoh
Kunihiko Itoh

1 February 2014 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
YYYoshinari Yokoyama
Yoshinari Yokoyama
MTMiho Tomatsuri
Miho Tomatsuri
HHHideki Hayashi
Hideki Hayashi
KHKeita Hirai
Keita Hirai
YOYasuo Ono
Yasuo Ono
KIKunihiko Itoh
Kunihiko Itoh

1 June 2014 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
KIKazuyuki Inoue
Kazuyuki Inoue
ESEri Bs Suzuki
Eri Bs Suzuki
RYRei Yazawa
Rei Yazawa
YYYoshiaki Msc Yamamoto
Yoshiaki Msc Yamamoto
TTToshiki Takahashi
Toshiki Takahashi
KIKunihiko Itoh
Kunihiko Itoh
Background: Valproic acid (VPA) is widely used to treat various types of epilepsy. Interindividual variability in VPA pharmacokinetics may arise from genetic polymorphisms of VPA-metabolizing enzymes. This study aimed to examine the relationships between plasma VPA concentrations and the −161C>T single nucleotide polymorphism in uridine diphosphate glucuronosyltransferase (UGT) 2B7 genes in pediatric epilepsy patients. Methods: This study included 78 pediatric epilepsy patients carrying the cytochrome P450 (CYP) 2C9*1/*1 genotype and who were not treated with the enzyme inducers (phenytoin, phenobarbital, and carbamazepine), lamotrigine, and/or topiramate. CYP2C9*3 and UGT2B7 −161C>T polymorphisms were identified using methods based on polymerase chain reaction–restriction fragment length polymorphism. Blood samples were drawn from each patient under steady-state conditions, and plasma VPA concentrations were measured. Results: Significant differences in adjusted plasma VPA concentrations were observed between carriers of CC, CT, and TT genotypes in the UGT2B7 −161C>T polymorphism (P = 0.039). Patients with the CC genotype had lower adjusted plasma VPA concentrations than those with CT or TT genotype (P = 0.028). Conclusions: These data suggest that the UGT2B7 −161C>T polymorphism in pediatric epilepsy patients carrying the CYP2C9*1/*1 genotype affects VPA concentration.

1 November 2016 in Medicine
Verified
Journal Article
Open access
DTDaiki Tsuji
Daiki Tsuji
MIMidori Ikeda
Midori Ikeda
KYKeisuke Yamamoto
Keisuke Yamamoto
HNHarumi Nakamori
Harumi Nakamori
YKYong-Il Kim
Yong-Il Kim
KIKunihiko Itoh
Kunihiko Itoh
Chemotherapy-induced neutropenia (CIN) is one of the major adverse events that necessitate chemotherapy dose reduction. This study aimed to evaluate the association between grade 4 neutropenia and genetic polymorphisms in breast cancer patients. In this genetic polymorphism association study, peripheral blood samples from 100 consecutive breast cancer outpatients, between August 2012 and September 2014, treated with doxorubicin and cyclophosphamide (AC) combination chemotherapy were genotyped for polymorphisms in adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1), cytochrome P450 (CYP) enzyme-coding genes (CYP2B6 and CYP3A5), glutathione S-transferase (GST), and excision repair cross-complementing 1 (ERCC1). Associations between grade 4 neutropenia and genotypes as well as risk factors were examined using multivariate logistic regression. From 100 patients, 32.0% had grade 4 neutropenia. Multivariate logistic regression analysis revealed that ERCC1 118C > T (odds ratio [OR], 3.43; 95% confidence interval [CI], 1.22–9.69; P = 0.020), CYP2B6*6 (OR, 4.51; 95% CI, 1.21–16.95; P = 0.025), body mass index (BMI) (OR, 6.94; 95% CI, 1.15–41.67; P = 0.035), and baseline white blood cell (WBC) count (OR, 2.99; 95% CI, 1.06–8.40; P = 0.038) were significant predictors of grade 4 neutropenia. ERCC1 and CYP2B6 gene polymorphisms were associated with the extent of grade 4 neutropenia in patients receiving AC chemotherapy. In addition to previously known risk factors, BMI and WBC counts, ERCC1 and CYP2B6 gene polymorphisms were also identified as independent strong predictors of grade 4 neutropenia.

9 July 2016 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
KHKeita Hirai
Keita Hirai
TSTatsuki Shimomura
Tatsuki Shimomura
HMHideaki Moriwaki
Hideaki Moriwaki
HIHidetoshi Ishii
Hidetoshi Ishii
TSTakayuki Shimoshikiryo
Takayuki Shimoshikiryo
KIKunihiko Itoh
Kunihiko Itoh